Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 2/20 | 0.52 |
| ▸ | KIF5B | P33176 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.47 |
| ▸ | RAF1 | P04049 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TNNI3K | Q59H18 | 4/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 3/20 | 0.41 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.41 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7043886 | 0.82 | MAPK8 (0.50) | RETKIF5BGAAKMT2ALMNA | |
| SCHEMBL7938078 | 0.79 | TRPA1 (0.54) | RETKIF5BGAAKMT2ALMNA | |
| Ammonia Solution, Strong SCHEMBL1317334 | 0.74 | MAPK8 (0.54) | RETKIF5BGAAKMT2ALMNA | |
| SCHEMBL5305091 | 0.73 | MAPK8 (0.57) | GAAKMT2ALMNAMAPTHTT | |
| SCHEMBL3228186 | 0.71 | MAPT (0.52) | GAAKMT2ALMNAMAPTKDM4E | |
| SCHEMBL11451246 | 0.70 | RET (0.41) | RETKIF5BGAAKMT2ALMNA | |
| SCHEMBL16785515 | 0.70 | RET (1.00) | RETKIF5BRAF1BRAFEGFR | |
| SCHEMBL11406396 | 0.69 | TRPA1 (0.52) | RETKIF5BGAAKMT2ALMNA | |
| SCHEMBL8310698 | 0.69 | TRPA1 (0.52) | RETKIF5BGAAKMT2ALMNA | |
| Hydrochloric Acid SCHEMBL16760376 | 0.69 | RET (0.98) | RETKIF5BRAF1BRAFEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110275640-A1 | Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound | BTG INTERNATIONAL LTD. (GB) | 2011-11-10 | — | — | US | disclosed |
| US-20110275641-A1 | Preventives or remedies for Alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound | BTG INTERNATIONAL LTD. (GB) | 2011-11-10 | — | — | US | disclosed |
| US-8003645-B2 | type II diabetes; 6-Ethyl-N,N'-bis(3-hydroxyphenyl)-1,3,5-triazine-2,4-diamine; suppress the fall in MTT reduction capacity by beta -amyloid protein; inhibit impairment of long-term potentiation of hippocampal nerve cells, pyrimidine or 1,3,5 triazine derivatives | BTG INTERNATIONAL LTD. (GB) | 2011-08-23 | — | — | US | disclosed |
| US-20090286809-A1 | Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound | BTG INTERNATIONAL LTD. (GB) | 2009-11-19 | — | — | US | disclosed |
| US-20090286794-A1 | Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound | BTG INTERNATIONAL LTD. (GB) | 2009-11-19 | — | — | US | disclosed |
| US-7589105-B2 | For example, N,N'-bis(3-hydroxyphenyl)pyrimidine-4,6-diamine, 2-methyl-N,N'-bis(3-hydroxyphenyl)pyrimidine-4,6-diamine | BTG INTERNATIONAL LIMITED (GB) | 2009-09-15 | — | — | US | disclosed |
| EP-1473289-B1 | PREVENTIVES OR REMEDIES FOR ALZHEIMER'S DISEASE OR AMYLOID PROTEIN FIBROSIS INHIBITORS CONTAINING NITROGEN-CONTAINING HETEROARYL COMPOUNDS | BTG INT LTD (GB) | 2009-08-05 | — | — | EP | disclosed |
| US-20080182846-A1 | Preventives or remedies for Alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound | BTG INTERNATIONAL LIMITED (GB) | 2008-07-31 | — | — | US | disclosed |
| US-20050054732-A1 | Preventives or remidies for alzheimer's disease or amyloid protein fibrosis inhibitors containing nitrogen-containing heteroaryl compounds | BTG INTERNATIONAL LTD. (GB) | 2005-03-10 | — | — | US | disclosed |
| EP-1473289-A1 | PREVENTIVES OR REMEDIES FOR ALZHEIMER'S DISEASE OR AMYLOID PROTEIN FIBROSIS INHIBITORS CONTAINING NITROGEN-CONTAINING HETEROARYL COMPOUNDS | Sankyo Company, Limited (JP) | 2004-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054732-A1 | Preventives or remidies for alzheimer's disease or amyloid protein fibrosis inhibitors containing nitrogen-containing heteroaryl compounds | NAT1, APP, BACE1 | RET 3236/4885KIF5B 2871/4885GAA 1762/4885 |
| US-20110275641-A1 | Preventives or remedies for Alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound | APP, BACE1, PSEN1 | RET 3859/4885KIF5B 2570/4885GAA 1351/4885 |
| US-20090286794-A1 | Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound | APP, BACE1, PSEN1 | RET 3859/4885KIF5B 2570/4885GAA 1351/4885 |
| US-20090286809-A1 | Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound | APP, BACE1, PSEN1 | RET 3859/4885KIF5B 2570/4885GAA 1351/4885 |
| US-20080182846-A1 | Preventives or remedies for Alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound | APP, BACE1, PSEN1 | RET 3859/4885KIF5B 2570/4885GAA 1351/4885 |
| US-20110275640-A1 | Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound | APP, BACE1, PSEN1 | RET 3859/4885KIF5B 2570/4885GAA 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.